Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.90    -0.10 (-3.33%)
Bid:
2.90
Ask:
3.00
Spread: 0.10 (3.448%)
Market Cap: £5.29m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Litigation Settlement Update

9 Jan 2023 07:00

RNS Number : 0156M
Nanoco Group PLC
09 January 2023
 

FOR IMMEDIATE RELEASE 9 January 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS THE SAME HAS BEEN RETAINED IN UK LAW AS AMENDED BY THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR").

 

Nanoco Group PLC

("Nanoco", the "Group", or the "Company")

 

Litigation Settlement Update

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from its technology platform, provides a further update on its proposed settlement with Samsung.

 

Nanoco announced on 6 January 2023 that a term sheet for a no fault settlement of the litigation had been agreed between Nanoco and Samsung (the "Parties"). The Parties have 30 days from that date to agree the full terms of a final settlement agreement and therefore jointly requested a stay to the trial that was scheduled to commence on 6 January. Following the announcement, the Judge in the case agreed to that joint motion for a 30 day stay just before midnight (GMT) on Friday 6 January.

 

The settlement process requires further negotiations and continues to operate within the control of the US judicial system, and hence the outcome of the litigation, its settlement, and timing are not wholly within the control of the Parties. As a result of these factors, the value and terms of any final agreement are not yet certain.

 

Details of the terms sheet and of any final agreement with Samsung are covered by a confidentiality agreement to protect the commercial interests of both Parties during the ongoing negotiations.

In evaluating the settlement offer and concluding that it provides a fair outcome for the Company and its shareholders, the Board, having consulted with its advisers in the litigation, took into account the following considerations:

· The gross settlement value should be expected to be towards the lower end of the range of expectations for a successful jury trial outcome as previously guided by the Company.

· A settlement removes the risks of the litigation process, potential appeal processes of the trial and the ongoing appeal of the Patent Trial and Appeal Board decisions, further litigation costs, and the time value of money.

· Historical precedent shows that any final agreement is likely to be a one off payment, with no forward royalties, for the full and final settlement of all current and future patent litigation between the Parties in all jurisdictions (colloquially referred to as "patent peace").

The Company expects to issue a further update on the final agreement following the completion of the further negotiations between the Parties.

Christopher Richards, Non-Executive Chairman of Nanoco, said:

"The Board, having taken extensive advice from its advisers in the case, has concluded that the draft settlement offer provides a reasonable and immediate fair value for the litigation. The draft settlement accounts for both the potential downside risks of a jury trial, followed by what would likely be very protracted appeal processes, as well as the considerable adverse impact of further litigation costs and funding, and on the time value of money in a rising interest rate environment. Whilst there is still a degree of uncertainty around the final settlement agreement, we are working with Samsung to finalise the detailed agreement within the allowed 30 day period and look forward to updating shareholders further in due course."

 

Brian Tenner, Chief Executive Officer of Nanoco, said:

"A settlement provides certainty to all our stakeholders and further reinforces our confidence in the validity and enforceability of the Group's global patent portfolio.

 

"I am more confident than ever about Nanoco's future prospects. A settlement provides a firm financial underpinning to focus on our organic business, which has made significant progress over the last three years. It also demonstrates the Company's willingness to vigorously defend our global IP portfolio against any potentially infringing parties in the wider market."

 

- Ends -

 

For further information, please contact:

Nanoco Group PLC:

Brian Tenner, CEO +44 (0)1928 761 404

Liam Gray, CFO & Company Secretary

 

Peel Hunt (Joint Corporate Broker):

Paul Gillam +44 (0) 20 7418 8900

James Smith

 

Turner Pope Investments (Joint Corporate Broker):

Andrew Thacker +44 (0) 20 3657 0050

James Pope

 

MHP: +44 (0) 203 128 8100

Reg Hoare

Pete Lambie

nanoco@mhpgroup.com

 

The person responsible for arranging for the release of this announcement on behalf of Nanoco is Liam Gray, Chief Financial Officer.

MAR

The information contained within this announcement is considered by the Company to contain inside information for the purposes of UK MAR. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.

 

FORWARD LOOKING STATEMENTS

This announcement (including information incorporated by reference in this announcement) and other information published by Nanoco may contain statements about Nanoco that are or may be deemed to be forward looking statements. Such statements are prospective in nature. All statements other than historical statements of facts may be forward looking statements. Without limitation, statements containing the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or "considers" or other similar words may be forward looking statements.

 

Forward looking statements inherently contain risks and uncertainties as they relate to events or circumstances in the future. Important factors such as business or economic cycles, the terms and conditions of Nanoco's financing arrangements, tax rates, or increased competition may cause Nanoco's actual financial results, performance or achievements to differ materially from any forward looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward looking statements, which speak only as of the date hereof. Nanoco disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law.

 

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots and other nano-materials. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display, Sensor and Electronics markets. An interesting property of quantum dots is their absorption spectrum. Nanoco's HEATWAVE™ quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectrum, rendering them useful for applications including image sensors. Another interesting property of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco was founded in 2001 and is headquartered in Runcorn, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

 

visit: www.nanocotechnologies.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFFVILAITIIV
Date   Source Headline
9th Dec 20217:00 amRNSBlock listing Six-Monthly Return
2nd Dec 20217:18 amRNSBlock Listing Application
1st Dec 202112:30 pmRNSDirector/PDMR Shareholding
1st Dec 202112:28 pmRNSAnnual General Meeting – Voting Results
30th Nov 20217:00 amRNSAGM Statement
18th Nov 20211:13 pmRNSDirector/PDMR Shareholding
9th Nov 20217:11 amRNSDirector/PDMR Shareholding
8th Nov 20217:00 amRNSDirector Appointment
5th Nov 202111:25 amRNSAdditional Work Package for European Customer
4th Nov 20216:20 pmRNSNotice of AGM
3rd Nov 20217:00 amRNSPreliminary Results
18th Oct 20216:10 pmRNSChange to final results announcement date
13th Oct 20219:30 amRNSPresentation via Investor Meet Company
8th Oct 20211:48 pmRNSNotice of Results
19th Aug 20217:00 amRNSNon-Executive Director Appointment
16th Jul 20214:41 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
15th Jul 20217:00 amRNSNon-dilutive loan note subscription
5th Jul 20217:30 amRNSDevelopment Agreement
28th Jun 20217:00 amRNSLitigation update and non-dilutive debt facility
10th Jun 202111:33 amRNSBlocklisting Six-Monthly Return
24th May 202112:20 pmRNSHolding(s) in Company
20th May 20217:00 amRNSLitigation Update
13th May 20217:00 amRNSProject Extension
12th May 20217:00 amRNSLitigation Update
6th May 20213:28 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSInterim Results
29th Mar 20217:00 amRNSLitigation Update
26th Mar 20214:41 pmRNSSecond Price Monitoring Extn
26th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20213:36 pmRNSAmendment to Executive Director Service Terms
16th Mar 20212:30 pmRNSNotice of Results
10th Feb 20214:40 pmRNSSecond Price Monitoring Extn
10th Feb 20214:35 pmRNSPrice Monitoring Extension
25th Jan 20214:41 pmRNSSecond Price Monitoring Extn
25th Jan 20214:35 pmRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202011:40 amRNSBlocklisting Six-Monthly Return
3rd Dec 202012:10 pmRNSResult of AGM
3rd Dec 20207:00 amRNSAGM Statement
25th Nov 20207:00 amRNSGrant Funding Award for Life Sciences Project
17th Nov 20205:50 pmRNS2020 Annual Report and Notice of AGM
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
21st Oct 20203:16 pmRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSPreliminary Results
7th Oct 20207:00 amRNSNotice of Results
25th Sep 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.